MIAMI, FL -- (MARKET WIRE) -- March 20, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”) announced today the formation of a North American Medical Advisory Board (“MAB”) to provide clinical guidance to the Company in anticipation of the potential US marketing approval for orBec® for the treatment of gastrointestinal Graft versus Host disease (“GI GVHD”). The MAB is made up of clinical and research physicians with extensive backgrounds in the field of allogeneic hematopoietic cell transplantation (“HCST”), the clinical setting that GI GVHD occurs within. The MAB will be chaired by George B. McDonald, MD, Professor of Medicine at the University of Washington, Member at the Fred Hutchinson Cancer Research Center, inventor of orBec®, and a consultant to DOR.
